Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Neoplasms 4Venous Thrombosis 2Venous Thromboembolism 2Pulmonary Embolism 2Thrombosis 1Small Cell Lung Carcinoma 1Hemorrhage 1Carcinoma, Small Cell 1

Interventions

Dalteparin 11apixaban 10Tinzaparin 5Enoxaparin 5Rivaroxaban 4Heparin, Low-Molecular-Weight 3Dabigatran 3edoxaban 2bemiparin 2abelacimab 2Warfarin 2MAA868 2Fondaparinux 2perflutren 1isoquercitrin 1enoxaparin sodium 1Sulfur Hexafluoride 1Rosuvastatin Calcium 1Phenprocoumon 1Nephrectomy 1Nadroparin 1Hospitals 1Heparin 1Fluorodeoxyglucose F18 1Educational Status 1Drug Delivery Systems 1Deoxyribonucleases 1Aspirin 1Acetylcysteine 1Acenocoumarol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Pulmonary Embolism × bemiparin × Clear all
NCT01727427 2019-08-08

Prospective Study on the Treatment of Unsuspected Pulmonary Embolism in Cancer Patients

G. d'Annunzio University

Completed
695 enrolled

Neoplasms, Pulmonary Embolism

NCT00219973 2010-04-28

CANBESURE STUDY (Cancer, Bemiparin and Surgery Evaluation)

Rovi Pharmaceuticals Laboratories

Phase 3 Completed
526 enrolled
Classical hematology

Hemorrhage, Neoplasms, Pulmonary Embolism, Venous Thrombosis, Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡